title: Ð¥Ð°ÑÐ°ÐºÑÐµÑÐ¸ÑÑÐ¸ÐºÐ° Ð¼Ð¾Ð½Ð¾ÐºÐ»Ð¾Ð½Ð°Ð»ÑÐ½ÑÑ Ð°Ð½ÑÐ¸ÑÐµÐ» Ðº Ð²Ð¸ÑÑÑÑ Ð³ÑÐ¸Ð¿Ð¿Ð° Ð/ÐÐ°ÑÑÐ°ÑÑÑÐµÑÑ/2/12 Ð¯Ð¼Ð°Ð³Ð°ÑÑÐºÐ¾Ð¹ ÑÐ²Ð¾Ð»ÑÑÐ¸Ð¾Ð½Ð½Ð¾Ð¹ Ð»Ð¸Ð½Ð¸Ð¸
title: Ð¼Ð°Ð³Ð¸ÑÑÐµÑÑÐºÐ°Ñ Ð´Ð¸ÑÑÐµÑÑÐ°ÑÐ¸Ñ
titleType: Subtitle
Creators: name: Ð¡Ð°Ð¹ÑÐ³Ð°Ð»Ð¸Ð½Ð°, ÐÐ°ÑÐ¸Ñ
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2016
Subjects: Ð¼ÑÑÐ°ÑÐ¸Ð¸
Ð²Ð¸ÑÑÑÑ Ð³ÑÐ¸Ð¿Ð¿Ð°
Ð¼Ð¾Ð½Ð¾ÐºÐ»Ð¾Ð½Ð°Ð»ÑÐ½ÑÐµ Ð°Ð½ÑÐ¸ÑÐµÐ»Ð°
Ð³ÐµÐ¼Ð°Ð³Ð³Ð»ÑÑÐ¸Ð½Ð¸Ð½
mutations
influenza viruses
monoclonal antibodies
hemagglutinin

description: Ð Ð¿ÑÐµÐ´ÐµÐ»Ð°Ñ Ð¾Ð´Ð½Ð¾Ð¹ ÑÐ²Ð¾Ð»ÑÑÐ¸Ð¾Ð½Ð½Ð¾Ð¹ Ð»Ð¸Ð½Ð¸Ð¸ Ð²Ð¸ÑÑÑÐ¾Ð² Ð³ÑÐ¸Ð¿Ð¿Ð° ÑÐ¸Ð¿Ð° Ð Ð¿ÑÐ¾Ð¸ÑÑÐ¾Ð´ÑÑ Ð¿Ð¾ÑÑÐ¾ÑÐ½Ð½ÑÐµ Ð¼ÑÑÐ°ÑÐ¸Ð¸ ÑÑÐ¶ÐµÐ»Ð¾Ð¹ ÑÑÐ±ÑÐµÐ´Ð¸Ð½Ð¸ÑÑ Ð¿Ð¾Ð²ÐµÑÑÐ½Ð¾ÑÑÐ½Ð¾Ð³Ð¾ Ð°Ð½ÑÐ¸Ð³ÐµÐ½Ð° Ð²Ð¸ÑÑÑÐ½Ð¾Ð¹ ÑÐ°ÑÑÐ¸ÑÑ, Ð³ÐµÐ¼Ð°Ð³Ð³Ð»ÑÑÐ¸Ð½Ð¸Ð½Ð°. Ð¢Ð°ÐºÐ¸Ð¼ Ð¾Ð±ÑÐ°Ð·Ð¾Ð¼, Ð²Ð¸ÑÑÑ ÑÐ¿Ð¾ÑÐ¾Ð±ÐµÐ½ ÑÑÐºÐ¾Ð»ÑÐ·Ð°ÑÑ Ð¾Ñ Ð´ÐµÐ¹ÑÑÐ²Ð¸Ñ Ð¸Ð¼Ð¼ÑÐ½Ð½ÑÑ Ð°Ð½ÑÐ¸ÑÐµÐ». Ð¦ÐµÐ»ÑÑ ÑÐ°Ð±Ð¾ÑÑ ÑÐ²Ð»ÑÐ»Ð°ÑÑ ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐºÐ° Ð¸ ÑÐ°ÑÐ°ÐºÑÐµÑÐ¸ÑÑÐ¸ÐºÐ° Ð½Ð¾Ð²ÑÑ Ð¼Ð¾Ð½Ð¾ÐºÐ»Ð¾Ð½Ð°Ð»ÑÐ½ÑÑ Ð°Ð½ÑÐ¸ÑÐµÐ» (ÐÐÐ), Ð½Ð°Ð¿ÑÐ°Ð²Ð»ÐµÐ½Ð½ÑÑ Ðº Ð³ÐµÐ¼Ð°Ð³Ð³Ð»ÑÑÐ¸Ð½Ð¸Ð½Ñ Ð²Ð¸ÑÑÑÐ° Ð³ÑÐ¸Ð¿Ð¿Ð° ÑÐ¸Ð¿Ð° Ð Ð¯Ð¼Ð°Ð³Ð°ÑÑÐºÐ¾Ð¹ ÑÐ²Ð¾Ð»ÑÑÐ¸Ð¾Ð½Ð½Ð¾Ð¹ Ð»Ð¸Ð½Ð¸Ð¸. ÐÑÐ»Ð¸ ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐ°Ð½Ñ Ð³ÐµÐ½ÐµÑÐ¸ÑÐµÑÐºÐ¸ ÑÑÐ°Ð±Ð¸Ð»ÑÐ½ÑÐµ ÑÑÐ°Ð¼Ð¼Ñ Ð¼ÑÑÐ¸Ð½ÑÑ Ð³Ð¸Ð±ÑÐ¸Ð´Ð¾Ð¼ - Ð¿ÑÐ¾Ð´ÑÑÐµÐ½ÑÐ¾Ð² ÐÐÐ Ðº Ð²Ð¸ÑÑÑÑ Ð³ÑÐ¸Ð¿Ð¿Ð° Ð/ÐÐ°ÑÑÐ°ÑÑÑÐµÑÑ/2/12. ÐÑÐ¿Ð¾Ð»ÑÐ·ÑÑ ÑÑÐ¸ Ð³Ð¸Ð±ÑÐ¸Ð´Ð¾Ð¼Ñ, ÑÐ´Ð°Ð»Ð¾ÑÑ Ð¿Ð¾Ð»ÑÑÐ¸ÑÑ Ð²Ð¾ÑÐµÐ¼Ñ ÐÐÐ. Ð¡ Ð¿Ð¾Ð¼Ð¾ÑÑÑ ÐÐ¤Ð Ð¸ Ð Ð¢ÐÐ Ð±ÑÐ»Ð° Ð¿Ð¾ÐºÐ°Ð·Ð°Ð½Ð° ÑÐ¿ÐµÑÐ¸ÑÐ¸ÑÐ½Ð¾ÑÑÑ ÑÑÐ¸Ñ Ð°Ð½ÑÐ¸ÑÐµÐ» Ðº Ð¯Ð¼Ð°Ð³Ð°ÑÑÐºÐ¸Ð¼ ÑÑÐ°Ð¼Ð¼Ð°Ð¼. ÐÐ½Ð°Ð»Ð¸Ð· ÑÑÐºÐµÐ¹Ð¿-Ð¼ÑÑÐ°Ð½ÑÐ¾Ð² Ð¸ÑÑÐ¾Ð´Ð½Ð¾Ð³Ð¾ Ð²Ð¸ÑÑÑÐ° (Ð/ÐÐ°ÑÑÐ°ÑÑÑÐµÑÑ/2/12) Ð¿Ð¾Ð·Ð²Ð¾Ð»Ð¸Ð» ÑÐ°Ð·Ð´ÐµÐ»Ð¸ÑÑ Ð¸ÑÑÐ»ÐµÐ´ÑÐµÐ¼ÑÐµ Ð¼Ð¾Ð½Ð¾ÐºÐ»Ð¾Ð½Ñ Ð½Ð° ÑÑÐ¸ Ð³ÑÑÐ¿Ð¿Ñ. ÐÐ°Ð¶Ð´Ð°Ñ Ð³ÑÑÐ¿Ð¿Ð° Ð°Ð½ÑÐ¸ÑÐµÐ» Ð½Ð°Ð¿ÑÐ°Ð²Ð»ÐµÐ½Ð° Ðº ÑÐ°Ð·Ð½ÑÐ¼ Ð°Ð½ÑÐ¸Ð³ÐµÐ½Ð½ÑÐ¼ ÑÐ°Ð¹ÑÐ°Ð¼ Ð¼Ð¾Ð»ÐµÐºÑÐ»Ñ Ð³ÐµÐ¼Ð°Ð³Ð³Ð»ÑÑÐ¸Ð½Ð¸Ð½Ð°, Ð´Ð²Ð° Ð¸Ð· ÐºÐ¾ÑÐ¾ÑÑÑ ÑÐ°ÑÑÐ¸ÑÐ½Ð¾ Ð¿ÐµÑÐµÐºÑÑÐ²Ð°ÑÑÑÑ.
description: Regular mutations take place in the heavy subunit of the viral antigen, hemagglutinin, within one evolutionary lineage of influenza B virus. Thus, virus is able to elude action of immune antibodies. The aim of this work was the development and characterization of new monoclonal antibodies (mAb) directed to the hemagglutinin of influenza B Yamagata-like evolutionary lineage viruses. Genetically stable strains of mouse hybridomas - producers of mAb to influenza virus B/Massachusetts/2/12, were developed. We got eight mAb using these hybridomas. We demonstrated antibodies specificity to Yamagata strains, using such methods as ELISA and hemagglutination-inhibition (HI) assay. Analysis of escape mutants of virus B/Massachusetts/2/12 allowed us to divide mAbs into three groups. Each group of antibodies is directed to different antigenic sites on the hemagglutinin molecule, two of which partially overlap.